CNS biotech Myrobalan Therapeutics raises $24M Series A to enter the clinic
10 Jan 2024
Myrobalan Therapeutics has raised $24 million to enter the clinic with one of its four CNS therapeutic candidates, with the goal of either repairing or restoring functions in patients with neurodegenerative conditions.
Neuroscience drug discovery and development has been heating up, with
recent
high-profile
approvals
, large
startup
financings
and a pair of
multi-billion
dollar
acquisitions
.
Medford, MA-based Myrobalan was formed in mid-2021 and is based on findings out of Harvard researcher Zhigang He, and has staff in China as well as the US. It’s a reunion of sorts for CEO Jing Wang, an 18-year biotech veteran who did her PhD in He’s lab in the early aughts. The biotech’s other co-founder is MIT professor Guoping Feng.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.